CONTACT US
Home > Inhibitors/Agonists>VEGFR> > Brivanib
649735-46-6-Brivanib Brivanib

Brivanib

For research use only. Not for therapeutic Use.

  • CAT Number: I004450
  • CAS Number: 649735-46-6
  • Molecular Formula: C₁₉H₁₉FN₄O₃
  • Molecular Weight: 370.38
  • Purity: ≥95%
Inquiry Now
Related products: Efetaal     Evodine     Cimicifugoside    

Brivanib (Cat No.:I004450) is a small-molecule tyrosine kinase inhibitor that targets multiple receptors involved in angiogenesis and tumor growth. It acts as an antagonist of vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), inhibiting their signaling pathways. This dual inhibition of VEGFR and FGFR may result in the suppression of tumor angiogenesis and the inhibition of tumor cell proliferation. Brivanib has shown promising anti-cancer activity in preclinical studies and has been evaluated in clinical trials for various types of solid tumors, including liver, colorectal, and gastric cancers.


Catalog Number I004450
CAS Number 649735-46-6
Synonyms

(2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol

Molecular Formula C₁₉H₁₉FN₄O₃
Purity ≥95%
Target VEGFR
Solubility DMSO: 50 mg/mL
Storage 3 years -20C powder
IC50 25 nM
IUPAC Name (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
InChI InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChIKey WCWUXEGQKLTGDX-LLVKDONJSA-N
SMILES CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
Reference

<br />
1:Application of In-line Focused Beam Reflectance Measurement to Brivanib Alaninate Wet Granulation Process to Enable Scale-up and Attribute-based Monitoring and Control Strategies. Narang AS, Stevens T, Macias K, Paruchuri S, Gao Z, Badawy S.J Pharm Sci. 2017 Jan;106(1):224-233. doi: 10.1016/j.xphs.2016.08.025. Epub 2016 Oct 19. PMID: 27771049 <br />
2:Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets. Badawy SI, Narang AS, LaMarche KR, Subramanian GA, Varia SA, Lin J, Stevens T, Shah PA.J Pharm Sci. 2016 Jan;105(1):168-81. doi: 10.1016/j.xphs.2015.11.023. Epub 2016 Jan 13. PMID: 26852852 <br />
3:Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, Moser CD, Shaleh HM, Thornburgh SR, Walters I, Roberts LR.PLoS One. 2015 Nov 3;10(11):e0142355. doi: 10.1371/journal.pone.0142355. eCollection 2015. No abstract available. PMID: 26528545 Free PMC Article<br />
4:Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib. Jia J, Qi X, Bai W, Yuan J, Han G.J Cancer Res Ther. 2014 Oct-Dec;10(4):1112-4. doi: 10.4103/0973-1482.144564. PMID: 25579566 Free Article<br />
5:Real-time assessment of granule densification in high shear wet granulation and application to scale-up of a placebo and a brivanib alaninate formulation. Narang AS, Sheverev VA, Stepaniuk V, Badawy S, Stevens T, Macias K, Wolf A, Pandey P, Bindra D, Varia S.J Pharm Sci. 2015 Mar;104(3):1019-34. doi: 10.1002/jps.24233. Epub 2014 Dec 2. PMID: 25470221 <br />
6:A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM.Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11. PMID: 25019571 Free PMC Article<br />
7:Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, Wu C, Tanwandee T, Shao G, Walters IB, Dela Cruz C, Poulart V, Wang JH.Hepatology. 2014 Nov;60(5):1697-707. doi: 10.1002/hep.27290. Epub 2014 Sep 29. PMID: 24996197 <br />
8:Systemic therapy in HCC: lessons from brivanib. Bolos D, Finn RS.J Hepatol. 2014 Oct;61(4):947-50. doi: 10.1016/j.jhep.2014.06.019. Epub 2014 Jun 24. No abstract available. PMID: 24972045 Free Article<br />
9:Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma. Song KD, Choi D, Lee JH, Im GH, Yang J, Kim JH, Lee WJ.AJR Am J Roentgenol. 2014 Jun;202(6):W559-66. doi: 10.2214/AJR.13.11042. PMID: 24848850 <br />
10:Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy. Badawy SI, Lin J, Gokhale M, Desai S, Nesarikar VV, LaMarche KR, Subramanian GA, Narang AS.Int J Pharm. 2014 Jul 20;469(1):111-20. doi: 10.1016/j.ijpharm.2014.04.059. Epub 2014 Apr 26. PMID: 24780101

Request a Quote